Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy L Comstock

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Ophthalmology and Therapy|December 16, 2014
Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis: 3-Year Results of a Randomized Clinical Trial in a Predominantly Asian PopulationVirender S Sangwan, P Andrew Pearson, Hemanth Paul, et al.
Clinical Ophthalmology (Auckland, N.Z.)|June 27, 2014
An update on the surgical management of pterygium and the role of loteprednol etabonate ointmentJohn D Sheppard, Arnulfo Mansur, Timothy L Comstock, et al.
Clinical Ophthalmology (Auckland, N.Z.)|May 14, 2010
Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitisTimothy L Comstock, Paul M Karpecki, Timothy W Morris, et al.
Ophthalmology|June 5, 2002
A 1-year prospective clinical trial of balafilcon a (PureVision) silicone-hydrogel contact lenses used on a 30-day continuous wear scheduleNoel A Brennan, M L Chantal Coles, Timothy L Comstock, et al.
Clinical Ophthalmology (Auckland, N.Z.)|March 9, 2011
Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgeryTimothy L Comstock, Michael R Paterno, Angele Singh, et al.
Clinical Drug Investigation|July 16, 2010
Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studiesTimothy L Comstock, Michael R Paterno, Heleen H Decory, et al.
Current Medical Research and Opinion|December 8, 2007
Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitisEric M White, Jonathan I Macy, Kirk M Bateman, et al.
Ophthalmology|January 19, 2010
Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitisCarlos Pavesio, Manfred Zierhut, Khaled Bairi, et al.
Paediatric Drugs|March 12, 2010
Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trialsTimothy L Comstock, Michael R Paterno, Dale W Usner, et al.
Clinical Ophthalmology (Auckland, N.Z.)|January 26, 2012
Post-cataract outcomes in patients with noninfectious posterior uveitis treated with the fluocinolone acetonide intravitreal implantJohn D Sheppard, Quan Dong Nguyen, Dale W Usner, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Ophthalmology and Therapy|December 16, 2014
Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis: 3-Year Results of a Randomized Clinical Trial in a Predominantly Asian PopulationVirender S Sangwan, P Andrew Pearson, Hemanth Paul, et al.
Clinical Ophthalmology (Auckland, N.Z.)|June 27, 2014
An update on the surgical management of pterygium and the role of loteprednol etabonate ointmentJohn D Sheppard, Arnulfo Mansur, Timothy L Comstock, et al.
Clinical Ophthalmology (Auckland, N.Z.)|May 14, 2010
Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitisTimothy L Comstock, Paul M Karpecki, Timothy W Morris, et al.
Ophthalmology|June 5, 2002
A 1-year prospective clinical trial of balafilcon a (PureVision) silicone-hydrogel contact lenses used on a 30-day continuous wear scheduleNoel A Brennan, M L Chantal Coles, Timothy L Comstock, et al.
Clinical Ophthalmology (Auckland, N.Z.)|March 9, 2011
Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgeryTimothy L Comstock, Michael R Paterno, Angele Singh, et al.
Clinical Drug Investigation|July 16, 2010
Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studiesTimothy L Comstock, Michael R Paterno, Heleen H Decory, et al.
Current Medical Research and Opinion|December 8, 2007
Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitisEric M White, Jonathan I Macy, Kirk M Bateman, et al.
Ophthalmology|January 19, 2010
Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitisCarlos Pavesio, Manfred Zierhut, Khaled Bairi, et al.
Paediatric Drugs|March 12, 2010
Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trialsTimothy L Comstock, Michael R Paterno, Dale W Usner, et al.
Clinical Ophthalmology (Auckland, N.Z.)|January 26, 2012
Post-cataract outcomes in patients with noninfectious posterior uveitis treated with the fluocinolone acetonide intravitreal implantJohn D Sheppard, Quan Dong Nguyen, Dale W Usner, et al.
Pageof 4